Adlai Nortye Ltd.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Non-accelerated filerEmerging growth company
State of Incorporation
DE
Business Address
685 U.S. HIGHWAY ONE, 2ND FLOOR, NORTH BRUNSWICK, NJ, 08902
Mailing Address
685 U.S. HIGHWAY ONE, 2ND FLOOR, NORTH BRUNSWICK, NJ, 08902
Phone
848-230-7430
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 20-F Foreign company annual report | April 10, 2026 | View on SEC |
| 6-K Foreign company current report | April 1, 2026 | View on SEC |
| 6-K Foreign company current report | February 12, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 11, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 9, 2026 | View on SEC |
| 6-K Foreign company current report | February 3, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 20, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 16, 2026 | View on SEC |
| 6-K Foreign company current report | December 29, 2025 | View on SEC |
| 6-K Foreign company current report | December 29, 2025 | View on SEC |
Annual Reports
20-F
April 10, 2026
- Advancing late-stage clinical trials for key drug candidates buparlisib and palupiprant.
- Strategic out-licensing business model leveraging partnerships with major firms like Novartis.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.